L’utilizzo del sodio oxibato (acido gamma-idrossibutirrico) nel trattamento ambulatoriale della sindrome di astinenza da alcol in pazienti affetti da cirrosi epatica

Maria Rita Quaranta; Vincenzo Ariano

doi:10.3280/mis68-2024oa19135

Newsletter "Clinica dell'Alcolismo"

N. 68 (2024)

L’utilizzo del sodio oxibato (acido gamma-idrossibutirrico) nel trattamento ambulatoriale della sindrome di astinenza da alcol in pazienti affetti da cirrosi epatica

Maria Rita Quaranta^▸^▾
Vincenzo Ariano^▸^▾

SCARICA QUI IL PDF

DOI: https://doi.org/10.3280/mis68-2024oa19135
Inviata: 10 gennaio 2025
Pubblicato: 20-02-2025

Riferimenti bibliografici

National Institute on Alcohol Abuse and Alcoholism. Alcohol use disorder. www.niaaa.nih.gov/alcohols-effectshealth/alcohol-use-disorder.
World Health Organization (2018). Global Status Report on Alcohol and Health.
World Health Organization (2024). Global status report on alcohol and health and treatment of substance use disorders.
Ginès P., Krag A., Abraldes J.G., Solà E., Fabrellas N., Kamath P.S. (2021). Liver cirrhosis. Lancet, Oct 9, 398(10308): 1359-1376.
Stein E., Cruz-Lemini M., Altamirano J. et al. (2016). Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol, 65: 998-1005.
Johnson A.L., Hayward K.L. (2021). Managing medicines in alcohol-associated liver disease: a practical review. Aust Prescr., Jun, 44(3): 96-106.
Addolorato G., Lesch O.M., Maremmani I., Walter H., Nava F., Raffaillac Q., Caputo F. (2020), Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. Expert Opin Drug Saf., Feb., 19(2): 159-166.
Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. (1989). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict., Nov., 84(11): 1353-7.
Caputo F., Skala K., Mirijello A. et al. (2014) Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial. CNS Drugs, 28: 743-752.
Felmlee M.A., Morse B.L., Morris M.E. (2021). γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology. AAPS J., Jan 8, 23(1): 22.
Salomoni M., Missanelli A., Crescioli G., Lanzi C., Totti A., Losso L., Gitto S., Bonaiuti R., Vannacci A., Lombardi N., Mannaioni G. (2024). Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis. Intern Emerg Med., Sep 9.
Caputo F., Casabianca A., Brazzale C., Lungaro L., Costanzini A., Caio G., De Giorgio R., Testino G., Piscaglia F., Caraceni P. (2024). Use of sodium oxybate for the treatment of alcohol withdrawal syndrome in patients with acute alcohol-associated hepatitis: A 4-patient case report. Medicine (Baltimore), Aug 2, 103(31), e39162.

Metriche

Caricamento metriche ...

Come citare

Quaranta, M. R., & Ariano, V. (2025). L’utilizzo del sodio oxibato (acido gamma-idrossibutirrico) nel trattamento ambulatoriale della sindrome di astinenza da alcol in pazienti affetti da cirrosi epatica. Mission - Open Access, (68). https://doi.org/10.3280/mis68-2024oa19135

[1] National Institute on Alcohol Abuse and Alcoholism. Alcohol use disorder. www.niaaa.nih.gov/alcohols-effectshealth/alcohol-use-disorder.

[2] World Health Organization (2018). Global Status Report on Alcohol and Health.

[3] World Health Organization (2024). Global status report on alcohol and health and treatment of substance use disorders.

[4] Ginès P., Krag A., Abraldes J.G., Solà E., Fabrellas N., Kamath P.S. (2021). Liver cirrhosis. Lancet, Oct 9, 398(10308): 1359-1376.

[5] Stein E., Cruz-Lemini M., Altamirano J. et al. (2016). Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol, 65: 998-1005.

[6] Johnson A.L., Hayward K.L. (2021). Managing medicines in alcohol-associated liver disease: a practical review. Aust Prescr., Jun, 44(3): 96-106.

[7] Addolorato G., Lesch O.M., Maremmani I., Walter H., Nava F., Raffaillac Q., Caputo F. (2020), Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. Expert Opin Drug Saf., Feb., 19(2): 159-166.

[8] Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. (1989). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict., Nov., 84(11): 1353-7.

[9] Caputo F., Skala K., Mirijello A. et al. (2014) Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial. CNS Drugs, 28: 743-752.

[10] Felmlee M.A., Morse B.L., Morris M.E. (2021). γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology. AAPS J., Jan 8, 23(1): 22.

[11] Salomoni M., Missanelli A., Crescioli G., Lanzi C., Totti A., Losso L., Gitto S., Bonaiuti R., Vannacci A., Lombardi N., Mannaioni G. (2024). Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis. Intern Emerg Med., Sep 9.

[12] Caputo F., Casabianca A., Brazzale C., Lungaro L., Costanzini A., Caio G., De Giorgio R., Testino G., Piscaglia F., Caraceni P. (2024). Use of sodium oxybate for the treatment of alcohol withdrawal syndrome in patients with acute alcohol-associated hepatitis: A 4-patient case report. Medicine (Baltimore), Aug 2, 103(31), e39162.